Recent Approvals in Targeted Therapy for Vitiligo

EP: 1.Overview of Vitiligo: Patient Demographics and Etiology

EP: 2.Differentiating Vitiligo From Other Hypopigmentation Skin Conditions

EP: 3.Initiating Patient Conversations on Vitiligo Diagnosis and QoL

EP: 4.Patient Education on Expectations for Vitiligo Treatment

EP: 5.Conventional and Nonconventional Treatment Approaches to Vitiligo

Now Viewing

EP: 6.Recent Approvals in Targeted Therapy for Vitiligo

EP: 7.Assessing Treatment Response in Patients With Vitiligo

EP: 8.Overcoming Barriers to Access for Vitiligo Treatment

EP: 9.Experts Excited by Advancements in Vitiligo Treatment

Panelists:

George Han, MD, PhD

Associate Professor, Donald and Barbara Zucker School of Medicine

Vice President, Dermatologic Society of Greater New York

Hofstra / Northwell

North New Hyde Park, New York

Susan C. Taylor, MD

Bernett Johnson Endowed Professor of Dermatology

Vice Chair for Diversity, Equity and Inclusion, Department of Dermatology Perelman School of Medicine, University of Pennsylvania

Philadelphia, Pennsylvania

Program Description:

In this video series, experts in the management of dermatological conditions discuss vitiligo and aim to set clear and realistic expectations for patients living with this condition. In the conversation they explore how to facilitate and engage their patients in a constructive conversation about the use of topical therapy for this condition emphasizing the importance of appropriate follow-up and monitoring practices to ensure treatment success.

Segment Description:

Dr Susan C. Taylor leads a discussion on newly approved agent, ruxolitinib, and its use in clinical practice as a targeted treatment option for patients with vitiligo.